Purpose: The Achieve inner lumen mapping catheter can be used with the cryoballoon to assess real-time isolation of pulmonary vein (PV) during cryoablation and to act as a supporting guidewire during balloon positioning. We sought to analyze the feasibility of this novel catheter and to assess real-time PV isolation during cryoablation. Methods: Patients undergoing 28-mm cryoballoon PVI using the Achieve catheter were included from two centers. Each application lasted 5 min. Realtime PV recording during freezing and time to PV isolation were analyzed. Lastly, the number of applications needed to achieve PV isolation was investigated. Results: 68 pts (47 male; 61±10 yo) were included. Averaged procedure duration and fluoroscopy times were 118±24 min and 29±10 min. During the first application, PV potentials could be detected during freezing in 95.2%, 75.0%, 81.5% and 31.2% of the left superior (LSPV), left inferior (LIPV), right superior (RSPV) and right inferior (RIPV) PVs, respectively. When PV potentials were detected, they appeared in 5±2, 4±2, 4±2, and 3±2 dipoles in and the first cryoenergy application was successful in 68.7%, 82.8%, 80.0% and 90.6% of the LSPVs, LIPVs, RSPVs, and RIPVs, respectively. PV deconnection occurred at -38.4±8.8°C/54.5±34.8sec, -33.3±10.5/46.9±30.4sec, -34.4±12.1/44.4±30.5sec and -37.4±18.0/52.7±27.1sec for the the LSPVs, LIPVs, RSPVs, and RIPVs, respectively. At the end of the procedure, 100% of the PVs were isolated after 1.2±0.6 applications (from 1 to 4).
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Purpose: In order to make atrial fibrillation (AF) ablation procedures safer and easier, new technologies have been developed leading to optimize cooling of the electrode-tissue interface. Recently, two different companies proposed two novel irrigated ablation catheters. The first, a flexible and fully-irrigated tip catheter with an innovative design to better adapt the ablation tip to the surrounding tissue and the second with a greater number of irrigation holes being able to increase and optimize the irrigation process. We thought to investigate procedural parameters and acute results in pulmonary vein isolation (PVI) comparing four different ablation catheters: "traditional" irrigated catheters and new catheters with a new irrigation tip design providing a more efficient cooling. Methods and results: One hundred thirty-one patients with paroxysmal atrial fibrillation (PAF) were consecutively enrolled and underwent PVI being divided in four Groups: 32 patients treated with Thermocool (Th) catheter (Group 1), 34 with Thermocool SF (SF) catheter (Group 2), 32 with Coolpath (CP) catheter (Group 3) and 33 with Coolflex (CF) catheter (Group 4). All groups were comparable for population characteristics. PVI was obtained in 100% of patients in all groups. Among procedural parameters, procedural time was significantly shorter using SF and CF catheter in comparison to Th and CP catheters, respectively (SF, 114 Introduction: Permanent coronary artery damage is a hazardous complication of epicardial radiofrequency ablation. Irreversible electroporation (IRE) is a promising non-thermal ablation modality able to create deep myocardial lesions. We investigated the effect of epicardial circular IRE-ablation on luminal coronary artery diameter. Methods: In a porcine model (5 pigs, 60-75 kg), the pericardium was exposed using surgical subxiphoidal epicardial access. A custom deflectable octopolar 12 mm circular catheter with 2 mm ring electrodes was introduced in the pericardial space via a steerable sheath. After coronary angiography (CAG), mid and distal LAD and RCx arteries were targeted with IRE-ablation. A single, non-arcing, nonbarotraumatic, cathodal 200 J application was delivered. After IRE-ablation and after 3 months follow-up, CAG was repeated. Luminal diameters of the artery proximal and distal to the lesion site were averaged with use of quantitative CAG (Q-CAG) and used as reference. Minimal luminal diameter at the lesion site was calculated with use of Q-CAG. Lesion width and depth were measured at autopsy. Results: CAG directly post-ablation demonstrated short-lasting luminal narrowing with normalization in the targeted area, suggestive of coronary spasm. After 3 months survival, all CAGs were identical to pre-ablation CAGs: mean reference luminal diameter was 2.3±0.4 mm, mean luminal diameter at the lesion site was 2.3±0.5 mm (p=0.822). Inspection at autopsy demonstrated presence of extensive epicardial lesions. Median lesion width and depth were 25 and 8 mm.
Catheter position over LAD and RCx
Conclusion:
Luminal coronary artery diameter remained unaffected 3 months after epicardial IRE-ablation, purposely targeting the coronary arteries. IREablation is a safe modality for catheter ablation on or near coronary arteries.
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Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation T. Evers 1 , A. Diamantopoulos 2 . 1 Bayer Pharma AG, Wuppertal, Germany; 2 Symmetron Limited, Elstree, United Kingdom Purpose: Discontinuation rates for vitamin K antagonists are high in patients with atrial fibrillation (AF). The aim of the current study was to assess the impact of real-life treatment persistence on the incidence of ischaemic strokes in patients with AF treated with a vitamin K antagonist or one of the newer oral anticoagulants (NOACs: rivaroxaban 20 mg, dabigatran 110 mg or dabigatran 150 mg). Methods: Real-life data on persistence from a US claims database and a German registry were combined to estimate the persistence rates for warfarin, dabigatran and rivaroxaban over 6 months and to calculate the mean duration on treatment. A model, accounting for switching patterns, was developed, combining these data with published ischaemic stroke rates for each treatment. The model assumed an annual risk of ischaemic stroke of 1.65% and 4.59% for patients receiving warfarin or no treatment, respectively. To obtain the risk of stroke for patients receiving NOACs, published relative risks were applied to the warfarin risk, giving an annual probability of stroke between 1.29% and 1.78%. Results: In the first 6 months, patients starting on warfarin stayed on treatment for a mean of 131 days before switching to another NOAC or stopping treatment completely. Patients starting on a NOAC had a longer duration on treatment (dabigatran [combined dose]: 149 days; rivaroxaban 20 mg: 168 days), before switching to warfarin or stopping treatment completely. The total ischaemic stroke risk at 6 months for each strategy was estimated to be 1.19% (warfarin), 1.12% (dabigatran 110 mg), 0.91% (dabigatran 150 mg) and 0.87% (rivaroxaban 20 mg). Compared with patients starting on warfarin, these risks translated into 7, 28 and 32 strokes avoided with dabigatran 110 mg, dabigatran 150 mg and rivaroxaban 20 mg, respectively, in a hypothetical cohort of 10,000 patients with AF. Conclusions: The model indicates that starting patients on a NOAC may decrease the total number of ischaemic strokes relative to warfarin therapy. Moreover, persistence rates should be considered in addition to treatment effects for the assessment of the overall value of oral anticoagulants, as better persistence may outweigh differences in risk reduction. Background: In recent European guidelines for the management of atrial fibrillation (AF) patients with CHADS2 score < 2 are considered to have low-moderate thromboembolic risk. Nonetheless, oral anticoagulation (OAC) is recommended in all situations to prevent embolic events. We assessed the risks and benefits of chronic OAC with CHADS2 score < 2, in patients submitted to PCI and stenting (PCI-S) requiring dual antiplatelet therapy (DAPT). Methods: A multicenter study was conducted from 2007 to 2011 to identify patients with non-valvular AF and low thromboembolic risk (CHADS2 < 2) who had undergone PCI-S. As clinical events to analize we considered bleeding events, thromboembolism, mortality, acute myocardial infarction or target revascularization and the composite of major adverse cardiac events (ie, death, acute myocardial infarction, and/or target lesion revascularization), as well as the composite of major clinical adverse events (ie, major adverse cardiac events, major bleeding, or thromboembolism). We analyzed retrospectively all recorded events post hoc after 1-year of follow-up. Results: We identified 640 consecutive patients with AF (75% male, 73.2±8.2 years). From this study cohort, 409 (29%) had a CHADS2 score < 2 and 51.7% of them were on OAC (45.4% on OAC plus DAPT, and 6.7% on OAC plus Clopidogrel). Baseline characteristics were similar between patients with and without OAC, including HASBLED score > 3 (15.5% vs 12.3%, p=0.22). At follow-up, patients on OAC showed a higher mortality (8.8% vs 4.1%, p=0.04) due an excess of cardiovascular death (7.4% vs 1.5%, p=0.004) and more major bleedings (7% versus 1%; P=0.002). However, they showed a lower incidence of thromboembolism (1.4% vs 5.7%, p=0.01). The incidence of major adverse cardiac events (13.5% versus 13.9%; P=0.51) and major adverse event (25.6% versus 24.2; % P=0.41) were similar between both treatment groups. A total of 27 patients (6.6%) died during follow-up, 19 (70.4%) were on OAC; 6 died because of a bleeding event, and 2 of them had CHADS2=1. In a multivariate analysis in patients with CHADS2 score < 2, treatment with OAC was predictor of an increased mortality (OR 2.4 95% CI 1.01 to 5.7%; p=0.04), due to an excess of cardiovascular mortality (OR 4.8 95% CI 1.33 to 17.43, p=0.017) . OAC was predictor of major bleeding too (OR 7.8: 1.7 to 35.5, p=0.008) . Conclusions: In patients with AF and CHADS2< 2 submitted to PCI-S, OAC increases mortality and major bleeding despite reducing thromboembolic events.
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Platelet reactivity monitoring in patients with atrial fibrillation treated with dabigatran Purpose: Dabigatran is a new oral anticoagulant that directly inhibits thrombin (factor IIa). Thrombin demonstrates multiple actions in physiologic (e.g. hemostasis, vasodilation) and pathophysiologic conditions (e.g. atherosclerosis, sepsis,etc.). Thus thrombin may mediate the bidirectional interactions between inflammatory and coagulation pathways. P-selectin,an inflammatory marker expressed on activated platelets surface, mediates platelet adherence to leukocytes (mainly monocytes and neutrophils). Several clinical studies have demonstrated efficacy of dabigatran in preventing venous thromboembolism (VTE) in patients undergoing elective total hip or knee replacement and in preventing strokes in patients with non valvular atrial fibrillation (AF), and in treating acute VTE. However, to date there are limited data about the effects of dabigatran on inflammation and atherogenesis. The aim of this study was to assess the effect of dabigatran on platelet aggregation, platelet-integrin receptor αIIb/β3 (GPIIb/IIIa) activation (PAC-1 binding), as well as on platelet-mediated inflammation (P-selectin) in comparison with warfarin in patients with non valvular AF. Methods: Patients suffered from AF (non valvular) and receiving warfarin were eligible for the study. 15 Patients switched from warfarin to dabigatran after informed consent. Blood samples were collected while on treatment with warfarin and 3-5 days after treatment with dabigatran. The platelet aggregatory response to ADP (20 μM and 5 μMu) or TRAP-14 (10 μM) was studied by Light Transmission Aggregometry (LTA). The surface expression of P-selectin and the PAC-1 binding either to resting or activated platelets was studied by flow cytometry in whole blood. Results: No difference between warfarin or dabigatran treatment was observed in platelet aggregation to both agonists as well as in PAC-1 expression in both resting and ADP-activated platelets. Similarly, no difference in P-selectin expression in resting platelets between warfarin or dabigatran treatment was observed (3,3±2,4 vs 2,5±0,9). Importantly, a significant reduction in P-selectin membrane expression was observed when patients were switched from warfarin to dabigatran after platelet activation with ADP (54,5±25,4 vs 18,4±8,2 respectively, P<0,05). Conclusions: We show for the first time that switch from warfarin to dabigatran in patients with AF, does not affect platelet aggregation and GPIIb/IIIa activation, but it reduces P-Selectin membrane expression which may represent an important anti-inflammatory and antiatherogenic activity of this potent direct thrombin inhibitor. Background: Atrial fibrillation (Af) is an important risk factor of stroke and left atrial appendage (LAA) is a major site of thrombus formation. CHADS2 score is a standard protocol for the determination of anticoagulation treatment in patients with Af. Thrombus of LAA can be identified by multi-detector contrast-enhanced computed tomography, whereas transesophageal echocardiography (TEE) is a traditional and promising method for identifying LAA thrombus. Aim: In this study, we attempted to investigate whether identifying thrombus in LAA by 320-row area-detector contrast-enhanced computed tomography (ADCT)
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